Department of Internal Medicine, MedStar Health, Baltimore, MD 21218, USA.
Department of Internal Medicine, Tufts Medical Center, Boston, MA 02111, USA.
Int J Mol Sci. 2022 Oct 14;23(20):12305. doi: 10.3390/ijms232012305.
The World Health Organization (WHO) refers to obesity as abnormal or excessive fat accumulation that presents a health risk. Obesity was first designated as a disease in 2012 and since then the cost and the burden of the disease have witnessed a worrisome increase. Obesity and hypertension are closely interrelated as abdominal obesity interferes with the endocrine and immune systems and carries a greater risk for insulin resistance, diabetes, hypertension, and cardiovascular disease. Many factors are at the interplay between obesity and hypertension. They include hemodynamic alterations, oxidative stress, renal injury, hyperinsulinemia, and insulin resistance, sleep apnea syndrome and the leptin-melanocortin pathway. Genetics, epigenetics, and mitochondrial factors also play a major role. The measurement of blood pressure in obese patients requires an adapted cuff and the search for other secondary causes is necessary at higher thresholds than the general population. Lifestyle modifications such as diet and exercise are often not enough to control obesity, and so far, bariatric surgery constitutes the most reliable method to achieve weight loss. Nonetheless, the emergence of new agents such as Semaglutide and Tirzepatide offers promising alternatives. Finally, several molecular pathways are actively being explored, and they should significantly extend the treatment options available.
世界卫生组织(WHO)将肥胖定义为异常或过度的脂肪积累,会对健康造成风险。肥胖于 2012 年首次被定为一种疾病,此后,肥胖相关的成本和负担呈令人担忧的上升趋势。肥胖和高血压密切相关,因为腹部肥胖会干扰内分泌和免疫系统,增加胰岛素抵抗、糖尿病、高血压和心血管疾病的风险。肥胖和高血压之间存在许多相互作用的因素。它们包括血流动力学改变、氧化应激、肾损伤、高胰岛素血症和胰岛素抵抗、睡眠呼吸暂停综合征以及瘦素-黑皮质素途径。遗传、表观遗传和线粒体因素也起着重要作用。在肥胖患者中测量血压需要使用适配的袖带,并且需要在高于一般人群的阈值下寻找其他继发性病因。生活方式的改变,如饮食和运动,往往不足以控制肥胖,到目前为止,减重手术是实现减肥的最可靠方法。尽管如此,新型药物如司美格鲁肽和替西帕肽的出现提供了有前景的替代方案。最后,一些分子途径正在积极探索,它们应该会大大扩展可用的治疗选择。